What question did this study set out to answer?

To establish the incidence and severity of auditory deficit and evaluate cochleotoxicity risk in cystic fibrosis patients undergoing repeated aminoglycoside therapy.

September 1, 2001Antimicrobial Agents and ChemotherapyOpen Access

Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy

View Full Paper

Ask AI

Bookmark

To establish the incidence and severity of auditory deficit and evaluate cochleotoxicity risk in cystic fibrosis patients undergoing repeated aminoglycoside therapy.
Evaluated 70 cystic fibrosis patients and 91 control subjects, stratified into pediatric and adult groups, using a retrospective design.
Administered standard (0.25- to 8-kHz) and extended high-frequency (10- to 16-kHz) pure-tone audiometry to assess hearing thresholds.
Aminoglycoside-induced hearing loss occurred in 12 of 70 cystic fibrosis patients (17.1%), including 1 pediatric patient.
The relationship between treatment courses and hearing loss incidence was nonlinear, severity did not correlate with course frequency, and the per-course risk was estimated at less than 2%.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study observes unexpectedly low rates of aminoglycoside cochleotoxicity in cystic fibrosis, suggesting underlying disease factors may confer protection against hearing loss.

Cite This Study

Mulheran et al. (2001) studied this question.

synapsesocial.com/papers/6a83eefa8f408d7d636a92ff https://doi.org/10.1128/aac.45.9.2502-2509.2001

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study observes unexpectedly low rates of aminoglycoside cochleotoxicity in cystic fibrosis, suggesting underlying disease factors may confer protection against hearing loss.

Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy

Key Points

Discussion

Implication

Cite This Study

Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider